The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.
作者信息
Meyer Jens E, Brocks Carsten, Graefe Hendrik, Mala Carola, Thäns Natalie, Bürgle Markus, Rempel Annette, Rotter Nicole, Wollenberg Barbara, Lang Stephan
机构信息
Department of Otorhinolaryngology and Facial Plastic Surgery, University Hospital Schleswig Holstein - Campus Lübeck, Germany.
出版信息
Breast Care (Basel). 2008;3(s2):20-24. doi: 10.1159/000151736. Epub 2008 Oct 16.
Abstract
摘要
相似文献
1
The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.
Breast Care (Basel). 2008;3(s2):20-24. doi: 10.1159/000151736. Epub 2008 Oct 16.
2
Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.
PLoS One. 2015 Sep 14;10(9):e0136725. doi: 10.1371/journal.pone.0136725. eCollection 2015.
3
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Thromb Haemost. 2005 Apr;93(4):779-86. doi: 10.1160/TH04-11-0712.
4
Loss of heterozygosity in mammary serine protease inhibitor (maspin) and p53 at chromosome 17 and 18 in oral cavity squamous cell carcinoma.
Head Neck. 2015 Sep;37(9):1239-45. doi: 10.1002/hed.23741. Epub 2014 Jul 10.
5
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
BMC Cancer. 2010 Mar 11;10:92. doi: 10.1186/1471-2407-10-92.
6
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3.
7
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
Br J Cancer. 2004 Mar 8;90(5):985-90. doi: 10.1038/sj.bjc.6601617.
8
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Ann Oncol. 2015 Mar;26(3):556-61. doi: 10.1093/annonc/mdu574. Epub 2014 Dec 18.
9
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005.
10
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Cancer. 2015 May 15;121(10):1599-607. doi: 10.1002/cncr.29251. Epub 2015 Jan 29.
引用本文的文献
1
Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment.
Cancer Med. 2025 Jan;14(1):e70550. doi: 10.1002/cam4.70550.
2
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.
Cancers (Basel). 2024 Mar 5;16(5):1050. doi: 10.3390/cancers16051050.
3
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Front Immunol. 2022 Dec 14;13:1060957. doi: 10.3389/fimmu.2022.1060957. eCollection 2022.
4
A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19.
Int J Infect Dis. 2023 Mar;128:148-156. doi: 10.1016/j.ijid.2022.12.003. Epub 2022 Dec 19.
5
Trypsin inhibitor LH011 inhibited DSS-induced mice colitis alleviating inflammation and oxidative stress.
Front Pharmacol. 2022 Sep 27;13:986510. doi: 10.3389/fphar.2022.986510. eCollection 2022.
6
Role of Serine Proteases at the Tumor-Stroma Interface.
Front Immunol. 2022 Feb 11;13:832418. doi: 10.3389/fimmu.2022.832418. eCollection 2022.
7
The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.
Int J Mol Sci. 2021 Dec 29;23(1):337. doi: 10.3390/ijms23010337.
8
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Int J Mol Sci. 2021 Apr 22;22(9):4358. doi: 10.3390/ijms22094358.
9
Small Ones to Fight a Big Problem-Intervention of Cancer Metastasis by Small Molecules.
Cancers (Basel). 2020 Jun 3;12(6):1454. doi: 10.3390/cancers12061454.
10
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018.
本文引用的文献
1
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Oral Oncol. 2005 Nov;41(10):971-7. doi: 10.1016/j.oraloncology.2005.05.013. Epub 2005 Aug 29.
2
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
Int J Cancer. 2004 Jul 20;110(6):815-24. doi: 10.1002/ijc.20192.
3
[Clinical and epidemiological data of patients with malignomas of the head and neck].
Laryngorhinootologie. 2002 Jul;81(7):499-508. doi: 10.1055/s-2002-33285.
4
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Expert Opin Biol Ther. 2001 Jul;1(4):683-91. doi: 10.1517/14712598.1.4.683.
5
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
J Natl Cancer Inst. 2001 Jun 20;93(12):913-20. doi: 10.1093/jnci/93.12.913.
6
7
The plasminogen activation system in tumor growth, invasion, and metastasis.
Cell Mol Life Sci. 2000 Jan 20;57(1):25-40. doi: 10.1007/s000180050497.
8
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Head Neck. 2000 Aug;22(5):498-504. doi: 10.1002/1097-0347(200008)22:5<498::aid-hed9>3.0.co;2-w.
9
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Eur J Cancer. 1998 Jul;34(8):1193-7. doi: 10.1016/s0959-8049(98)00029-x.
10
Zotero 插件